Ignite Creation Date:
2024-05-05 @ 4:41 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00293488
Status:
COMPLETED
Last Update Posted:
2016-06-23
First Post:
2006-02-16
Brief Title:
SL-11047 in Treating Patients With Relapsed or Refractory Lymphoma
Sponsor:
Progen Pharmaceuticals
Organization:
Progen Pharmaceuticals
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Lymphoma |
Keywords:
| Name | View |
|---|---|
| splenic marginal zone lymphoma | View |
| anaplastic large cell lymphoma | View |
| angioimmunoblastic T-cell lymphoma | View |
| extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue | View |
| nodal marginal zone B-cell lymphoma | View |
| recurrent adult Burkitt lymphoma | View |
| recurrent adult diffuse large cell lymphoma | View |
| recurrent adult Hodgkin lymphoma | View |
| recurrent adult T-cell leukemialymphoma | View |
| recurrent cutaneous T-cell non-Hodgkin lymphoma | View |
| recurrent grade 1 follicular lymphoma | View |
| recurrent grade 2 follicular lymphoma | View |
| recurrent grade 3 follicular lymphoma | View |
| recurrent mantle cell lymphoma | View |
| recurrent marginal zone lymphoma | View |
| recurrent mycosis fungoidesSezary syndrome | View |